Abbott’s stock falls by nearly 11% following Q4 sales miss

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a 5.7% increase on FY24. The fall of the healthcare giant’s stock primarily appears to be down to its Q4 2025 financials, which were released alongside the FY25 financials ahead of market open on 22 January. For Q4 2025, Abbott achieved revenues of $11.46bn, falling short of analysts’ expectations of $11.80bn, according to London Stock Exchange Group (LSEG) data seen by Reuters. Abbo ...